cgp 52411 has been researched along with erbstatin in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ito, M; Kitamura, T; Kiyoi, H; Naoe, T; Omura, S; Saito, H; Towatari, M; Ueda, R; Yamamoto, Y; Zhao, M | 1 |
1 other study(ies) available for cgp 52411 and erbstatin
| Article | Year |
|---|---|
In vivo treatment of mutant FLT3-transformed murine leukemia with a tyrosine kinase inhibitor.
Topics: Animals; Antineoplastic Agents; Benzoquinones; Cell Line, Transformed; Cell Transformation, Neoplastic; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Female; fms-Like Tyrosine Kinase 3; Genistein; Humans; Hydroquinones; Interleukin-3; Lactams, Macrocyclic; Leukemia, Experimental; Mice; Mice, Inbred C3H; Neoplasm Proteins; Neoplasm Transplantation; Phosphorylation; Phthalimides; Protein Processing, Post-Translational; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Quinones; Receptor Protein-Tyrosine Kinases; Rifabutin; Signal Transduction; Transfection; Tyrphostins | 2000 |